Dr. Reddy's Labs Files Q3 2025 6-K Report

TL;DR

DRL filed its Q3 2025 6-K, check it for performance updates.

AI Summary

Dr. Reddy's Laboratories Ltd. filed a Form 6-K on October 24, 2025, reporting for the quarter ended September 30, 2025. The company, based in Hyderabad, India, is a foreign private issuer filing under the 1934 Act. This filing is in addition to their regular Form 20-F filings.

Why It Matters

This filing provides an update on Dr. Reddy's Laboratories' financial and operational status for the third quarter of 2025, which is crucial for investors to assess the company's performance and make informed decisions.

Risk Assessment

Risk Level: low — This is a routine periodic filing by a foreign private issuer and does not contain new material events or significant financial changes.

Key Players & Entities

• DR REDDYS LABORATORIES LTD (company) — Filer
• 0001575872-25-000631 (accession_number) — Filing identifier
• 20251024 (date) — Filing date
• September 30, 2025 (date) — Quarter end date
• 1-15182 (sec_file_number) — SEC file number

FAQ

Key Financial Figures

• $1.00 — certified foreign exchange rate of U.S.$1.00 = Rs.88.78, as published by Federal Res

Filing Documents

• rdy0810_6k.htm (6-K) — 1108KB
• rdy0810_ex99-1.htm (EX-99.1) — 6KB
• 0001575872-25-000631.txt ( ) — 1115KB

Forward-Looking Statements and Risk Factor Summary

Forward-Looking Statements and Risk Factor Summary In addition to historical information, this quarterly report contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, risks relating to: • our business and operations in general, including: our ability to develop and commercialize additional pharmaceutical products; manufacturing, safety or quality control problems, which may damage our reputation for quality production and require costly remediation; interruptions in our supply chain; disruptions of our or third party information technology systems or breaches of our data security or other cyber-attacks; the failure to recruit or retain key personnel; significant sales to a limited number of customers in our U.S. market; and our ability to successfully undertake licensing opportunities; • our generics medicines business, including: consolidation of our customer base and commercial alliances among our customers; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; price erosion relating to our gener

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS 5

OPERATING AND FINANCIAL REVIEW, TREND INFORMATION

ITEM 2. OPERATING AND FINANCIAL REVIEW, TREND INFORMATION 44

LIQUIDITY AND CAPITAL RESOURCES

ITEM 3. LIQUIDITY AND CAPITAL RESOURCES 53

OTHER MATTERS

ITEM 4. OTHER MATTERS 55

EXHIBITS

ITEM 5. EXHIBITS 55

SIGNATURES

SIGNATURES 56 EXHIBIT 99.1: REVIEW REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 4

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS DR. REDDY’S LABORATORIES LIMITED AND SUBSIDIARIES UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION (in millions, except share and per share data) As of Particulars Note September 30, 2025 September 30, 2025 March 31, 2025 Convenience translation (See Note 2(e)) ASSETS Current assets Cash and cash equivalents 4 U.S.$ 112 Rs. 9,906 Rs. 14,654 Other investments 5 675 59,906 43,254 Trade and other receivables 6 1,101 97,738 90,420 Inventories 7 854 75,821 71,085 Derivative financial instruments 1 114 557 Other current assets 8 406 36,032 30,142 Total current assets U.S.$ 3,148 Rs. 279,517 Rs. 250,112 Non-current assets Property, plant and equipment 9 U.S.$ 1,261 Rs. 111,981 Rs. 97,761 Goodwill 10 139 12,298 11,810 Other intangible assets 11 1,137 100,942 96,803 Investment in equity accounted investees 58 5,184 4,811 Other investments 5 52 4,581 10,391 Deferred tax assets 256 22,717 18,508 Tax assets 42 3,713 1,821 Other non-current assets 8 12 1,072 972 Total non-current assets U.S.$ 2,957 Rs. 262,488 Rs. 242,877 Total assets U.S.$ 6,105 Rs. 542,005 Rs. 492,989 LIABILITIES AND EQUITY Current liabilities Trade and other payables U.S.$ 453 Rs. 40,248 Rs. 35,523 Short-term borrowings 13 464 41,155 38,045 Long-term borrowings, current portion 13 65 5,747 857 Provisions 74 6,548 6,168 Tax liabilities 86 7,628 3,028 Derivative financial instruments 32 2,836 1,286 Other current liabilities 12 527 46,765 45,485 Total current liabilities U.S.$ 1,700 Rs. 150,927 Rs. 130,392 Non-current liabilities Long-term borrowings 13 U.S.$ 131 Rs. 11,637 Rs. 7,864 Deferred tax liabilities 167 14,827 14,108 Provisions 2 173 156

View Full Filing

View this 6-K filing on SEC EDGAR